The new DTPw-HBV-Hib combination vaccine can be used at the who schedule with a monovalent dose of hepatitis B vaccine at birth.
Southeast Asian J Trop Med Public Health
;
1998 Dec; 29(4): 772-8
Article
in English
| IMSEAR
| ID: sea-33980
ABSTRACT
An open, randomized, clinical trial was conducted in order to assess the reactogenicity and immunogenicity of DTPw-HBV and Haemophilus influenzae type b (Hib) vaccines when given either as a mixed administration or as separate concomitant injections using the WHO schedule at 6, 10 and 14 weeks of age, following a dose of HBV at birth. There were no clinically relevant differences in the immune response to any component between the mixed and separate administrations. In fact the anti-tetanus GMTs were significantly higher (p=0.002) in mixed administration (3.9 IU/ml) compared with the separate administration (1.9 IU/ml). However although all subjects achieved anti-PRP titers > or = 0.15 microg/ml, higher anti-PRP GMTs were seen in the group receiving the separate administration. Importantly, the addition of Hib did not adversely alter the reactogenicity profile of DTPw-HBV. This report which demonstrates that this novel combination can be used in WHO recommended schedule.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Infant, Newborn
/
Influenza Vaccines
/
Diphtheria-Tetanus-Pertussis Vaccine
/
Haemophilus influenzae
/
Analysis of Variance
/
Hepatitis B Vaccines
/
Drug Combinations
/
Antibodies, Viral
Type of study:
Controlled clinical trial
Language:
English
Journal:
Southeast Asian J Trop Med Public Health
Year:
1998
Type:
Article
Similar
MEDLINE
...
LILACS
LIS